HanchorBio Advances Its Myeloid Enhancer Platform at BioCon China Expo 2026
HCB101 provides the clinical anchor for a broader platform spanning cancer combinations,
new therapeutic programs and autoimmune disease
TAIPEI, SHANGHAI, and SAN FRANCISCO — September 14, 2026 — HanchorBio Inc. (TWSE: 7827), a clinical-stage biotechnology company developing next-generation immunotherapies through its proprietary FBDB™ platform, today announced that Founder and Chairman Dr. Scott Liu will present at BioCon China Expo 2026 on September 15.
His presentation, “Reinvigorating Immunotherapy through a Myeloid Enhancer Platform,” will outline HanchorBio’s strategy to use HCB101 as the clinical anchor for a broader myeloid platform, extending the biology across multiple cancer combinations, additional pipeline programs, and autoimmune disease.
HCB101 is the clinical anchor. The broader opportunity is to extend the same myeloid biology across indications, treatment combinations, and FBDB™-derived programs.
Beyond T Cells: Adding Another Layer to Immunotherapy
PD-1/PD-L1 checkpoint inhibitors transformed cancer treatment by reinvigorating T-cell immunity, but many patients still do not respond or eventually develop resistance.
HanchorBio’s Myeloid Enhancer Platform is designed to activate upstream innate immunity and add a complementary layer to existing cancer therapy.
The Company’s lead clinical asset, HCB101, is an engineered SIRPα–Fc fusion protein designed to block the CD47–SIRPα “don’t eat me” checkpoint and restore macrophage-mediated tumor-cell phagocytosis.
Beyond direct tumor clearance, macrophage activation may promote antigen processing and presentation, remodel the tumor microenvironment, and support downstream T-cell responses — creating a mechanistic bridge between innate and adaptive immunity.
HanchorBio is evaluating HCB101 as a potential myeloid immune backbone alongside PD-1/PD-L1 inhibitors, Fc-active antibodies, VEGF-directed therapies, ADCs, chemotherapy, and vaccines.
One Clinical Anchor. Multiple Paths for Expansion.
Early clinical signals with HCB101 have been observed across gastric cancer, colorectal cancer, and head and neck squamous cell carcinoma, supporting continued evaluation across multiple tumor types and treatment settings.
The ongoing HCB101-201 Phase 1b/2a study (NCT06771622) is evaluating HCB101 with standard-of-care regimens across multiple cohorts, creating opportunities for indication expansion, new combinations, and strategic collaboration.
HanchorBio is also extending the same myeloid biology beyond oncology through HCB206, its next-generation CD20 × SIRPα program for autoimmune disease. Preclinical studies have demonstrated B-cell depletion across peripheral blood and lymphoid tissues, together with reductions in disease-associated biomarkers in systemic lupus erythematosus models.
One Clinical Anchor. A Much Broader Platform.
“HCB101 is important not only because of what one molecule may achieve, but because of what it can teach us about an entire area of immune biology,” said Scott Liu, PhD, Founder and Chairman of HanchorBio. “If we can establish myeloid activation clinically, we can build from that foundation across indications, combinations, new molecules, and new diseases.”
Through BioCon China Expo 2026, HanchorBio aims to engage global biopharma and industry partners around strategic collaboration, combination development, and global expansion of its Myeloid Enhancer Platform.
About HanchorBio
HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company dedicated to reinventing immunotherapies through its proprietary FBDB™ platform. By targeting innate and adaptive immune pathways, HanchorBio develops breakthrough biologics designed to overcome treatment resistance in oncology and immune-mediated diseases.
Forward-Looking Statements
This press release contains forward-looking statements regarding HanchorBio’s clinical development programs, product candidates, regulatory strategy, and future plans. Actual results may differ materially from those expressed or implied due to various risks and uncertainties, including clinical development outcomes, regulatory decisions, and market conditions. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.
漢康生技將於 BioCon China Expo 2026 分享巨噬細胞增強平台與免疫治療布局
創辦人、董事長暨執行長劉世高博士將發表主題演講，持續深化漢康於髓系免疫領域的產業定位，並拓展全球合作與技術交流機會
漢康生技（TWSE：7827）宣布，創辦人、董事長暨執行長劉世高博士將出席 BioCon China Expo 2026 第十三屆國際生物藥技術年會，並將於9月15日「雙多／單抗」論壇發表題為「透過巨噬細胞增強平台，重塑免疫治療」的主題演講。大會於9月15至 16日在上海浦東嘉里大酒店舉行。
BioCon China Expo 為生物藥產業年度交流平台之一，大會預計匯聚逾 200 位產業講者及 3,000 多名產業人士，議題涵蓋全球商務開發、雙／多特異性抗體、ADC-XDC、細胞治療、核酸藥物及 AI 製藥等生物醫藥前沿領域。
活動資訊
BioCon China Expo 2026 第十三屆國際生物藥技術年會
日期：2026 年 9 月 15–16 日
地點：上海浦東嘉里大酒店
演講時間：2026 年 9 月 15 日 09：15-09：45
演講主題：透過巨噬細胞增強平台，重塑免疫治療
講者：漢康生技創辦人、董事長暨執行長 劉世高博士
場次：「雙多／單抗」論壇
本次演講將聚焦漢康以巨噬細胞及髓系免疫為核心的下一代免疫治療策略，並分享公司如何透過FBDB™多功能生物藥平台，建構具差異化的免疫治療產品組合。透過由先天免疫切入腫瘤微環境，漢康持續探索巨噬細胞與其他免疫機制協同作用的治療潛力，並推進相關候選藥物的臨床與產品開發。
演講亦將以核心候選藥物 HCB101 為例，介紹透過阻斷 CD47–SIRPα 訊號、恢復巨噬細胞吞噬作用，進一步促進抗原呈現、腫瘤微環境重塑及 T 細胞活化的作用機制，並分享其於胃癌、結直腸癌及頭頸癌等實體腫瘤的臨床與轉譯研究進展。此外，也將介紹公司如何將髓系免疫策略延伸至 HCB206，以多重免疫效應機制探索更深度且持久的 B 細胞清除，拓展自體免疫疾病的治療潛力。
劉世高表示，參與BioCon等具產業影響力的國際生物醫藥會議，不僅是分享研發成果，更是持續建立公司在髓系免疫與多功能生物藥領域技術定位的重要一環。透過與跨國藥廠、生技公司、商務開發及投資機構交流，公司可進一步提升 FBDB™ 平台及產品管線的產業能見度，促進對漢康技術差異化與長期開發價值的理解，並為後續全球授權、策略合作及國際布局創造更多交流機會。BioCon本身亦以全球合作、跨境授權、投融資及產業對接為重要議題。
漢康將持續透過國際學術及產業平台，向全球合作夥伴分享公司於髓系免疫、新一代多功能生物藥及臨床開發上的進展，進一步深化全球生技產業連結，推動公司技術平台與產品管線的長期價值。
關於漢康生技
漢康生技（TWSE：7827）是一家全球臨床階段生技公司，運用自主開發的 FBDB™ 平台，致力於開發癌症及免疫介導疾病的下一代創新生物藥。漢康生技目前產品線包括已進入臨床階段的 HCB101 與 HCB301、下一代三特異性候選藥物 HCB303，以及其他針對癌症與免疫介導疾病的研發候選藥物。